Bipin Savani MD

Dr. Bipin N. Savani's area of specialization is in the treatment of hematological malignancies, stem cell transplantation/ cellular therapy, and his primary field of research is in the long-term follow-up after transplantation/ cellular therapy, including regimen-related toxicity/ supportive care, and outcomes analysis of hematological malignancies, transplant, and cellular therapy recipients.

Dr. Savani has published over 500 peer-reviewed articles, reviews, book chapters, editorials, perspectives, and commentaries in the field of hematological malignancies, stem cell transplantation, and cellular therapy. He is Co-Editor-in-Chief of journals Bone Marrow Transplantation (EBMT journal) and Clinical Hematology International (IACH journal) and associate editor of the British Journal of Haematology (BSH), Transplantation and Cellular Therapy (ASTCT journal, formerly BBMT), eJHaem (sister journal BJH); and also serves as an editorial advisory board member for several journals in the field.

Dr. Savani is currently the leader of the Conditioning Regimen Subcommittee of the Acute Leukemia Working Party of the EBMT. He also serves as Co-Chair of Regimen-Related Toxicity and Supportive Care-CIBMTR and medical monitor for Blood and Marrow Transplant Clinical Trial Network (BMT-CTN). Dr Savani is a member of the ASH Committee on Practice (COP) and a liaison member from the COP to the ASH Task Force on Immunotherapies subcommittee. He has recently edited several special issues for Seminars in Hematology, Hematology/ Oncology Clinics of North America and edited Wiley books entitled "Blood and Marrow Transplantation Long Term Management: Prevention and Complications" (first ed 2014, second ed May 2021) and "Clinical guide to transplantation in lymphomas" (first ed 2015). Co-authored handbook on Leukemia (FAST FACTS: Leukemia, first ed 2019). He has served as a Foundation for the Accreditation of Cellular Therapy (FACT) adults program clinical/ marrow collection facilities and Immune Effector Cell (IEC) inspector role since 2011.